Poging GOUD - Vrij
Exciting time for digital health players
BioSpectrum Asia
|March 2020
Digital Health has gained much importance, development and investment in the last decade. The year 2019, continued the strong upward trend in health innovation funding. With $13.7 billion in total funding across 727 deals, and was the second most-funded year ever, according to Startup Health. Boasting three out of 2019’s top 10 most-funded cities, China cemented its place as a hub for health innovation, and is positioned for continued growth. The last decade saw the emergence of telemedicine, Big Data, disruption in consumer wellness and healthcare, etc. As the digital health industry matures, there will be new challenges pertaining to data privacy, regulations, digital medicines, etc. Let’s look at the possibilities for digital health in the coming decade.

The global digital health market was valued at $ 144.2 billion in 2018 and is expected to reach a value of $393.3 billion by 2024, registering a CAGR of around 18 per cent during 2019-2024, according to the IMARC Group. The digital health market is slowly maturing from a sector dominated by early-stage start-ups to more established companies with validated products. 2019 was marked with the IPOs of several digital companies, some were acquired by Big Tech, and others partnered with Pharma firms from automating clinical trials to drug discovery. Analysis from Rock Health indicates that investments in digital healthcare in 2019 are keeping pace with investments that were made in 2018. While the total number of deals seems likely to stay consistent with 2018, the average size of the deals has increased.
Privacy is paramount
In the recent times, there has been increasing number of hacking-related to healthcare whether it’s WannaCry in 2017 which affected hospitals throughout the world or SingHealth’s (Singapore’s largest group of healthcare institutions) database containing patient personal particulars and outpatient dispensed medicines had been the target of a major cyber-attack in July 2018. These instances have put light on the privacy challenges these smart technologies bring. The privacy concern also cast a dark show over the growth of digital health industry.
Moving forward, digital healthcare companies will have to establish increasingly tight security, stringent privacy policies, and provide more transparency around data use.
Big Tech is big
Dit verhaal komt uit de March 2020-editie van BioSpectrum Asia.
Abonneer u op Magzter GOLD voor toegang tot duizenden zorgvuldig samengestelde premiumverhalen en meer dan 9000 tijdschriften en kranten.
Bent u al abonnee? Aanmelden
MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
2 mins
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Quantum Computing: Future of diagnostics is being coded today
A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.
4 mins
BioSpectrum Asia Sep 2025
BioSpectrum Asia
First Pacific woman to serve as public health director in NZ
The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Hugel launches botulinum toxin Letybo in Malaysia
South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Australia designs smart wound monitor to improve chronic infection care
Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Revvity unveils innovative reagent technology to accelerate therapeutics development
US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B
Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education
HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI
Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.
1 min
BioSpectrum Asia Sep 2025
Translate
Change font size